
  
    
      
        Background_NNP
        Converging_NNP points_NNS of_IN evidence_NN implicate_VB infection_NN by_IN
        high-risk_JJ human_JJ papilloma_NN virus_NN (_( HPV_NNP )_) types_NNS as_IN a_DT critical_JJ
        etiologic_JJ factor_NN in_IN cervical_JJ tumorigenesis_NNS [_NN 1_CD ]_NN ._.
        Epidemiological_NNP and_CC experimental_JJ data_NNS ,_, however_RB ,_, show_NN that_IN
        only_RB a_DT small_JJ fraction_NN of_IN HPV-infected_NNP cervical_JJ
        intraepithelial_NN neoplastic_JJ (_( CIN_NNP )_) lesions_NNS progress_NN to_TO
        invasive_JJ cervical_JJ carcinoma_NN (_( CC_NNP )_) [_NN 2_CD ]_NN ._. These_DT findings_NNS
        suggest_VBP somatic_JJ genetic_JJ mutations_NNS play_VBP a_DT critical_JJ role_NN in_IN
        the_DT initiation_NN and_CC progression_NN of_IN CC_NNP ._. Delineation_NNP of_IN these_DT
        genetic_JJ changes_NNS is_VBZ crucial_JJ to_TO understanding_VBG the_DT molecular_JJ
        basis_NN of_IN CC_NNP ._. A_DT number_NN of_IN genetic_JJ changes_NNS have_VBP been_VBN
        identified_VBN so_RB far_RB in_IN invasive_JJ CC_NNP ._. However_RB ,_, the_DT precise_JJ
        mechanism_NN of_IN each_DT of_IN these_DT genetic_JJ alterations_NNS in_IN the_DT
        multi-step_JJ pathway_NN of_IN cervical_JJ tumor_NN development_NN is_VBZ largely_RB
        unknown_JJ ._. The_DT development_NN of_IN CC_NNP is_VBZ preceded_VBN by_IN distinct_JJ
        morphological_JJ changes_NNS from_IN normal_JJ epithelium_NN to_TO carcinoma_NN
        through_IN low-grade_JJ and_CC high-grade_JJ squamous_JJ intraepithelial_NN
        lesions_NNS (_( SILs_NNP )_) ._. The_DT genetic_JJ basis_NN of_IN this_DT progression_NN is_VBZ
        also_RB poorly_RB understood_VBN ._.
        Cytogenetic_NNP and_CC molecular_JJ genetic_JJ analyses_NNS have_VBP
        identified_VBN the_DT short_JJ arm_NN of_IN chromosome_NN 5_CD ,_, 5_CD p_NN ,_, as_RB frequently_RB
        affected_VBN by_IN duplications_NNS and_CC deletions_NNS in_IN a_DT high_JJ proportion_NN
        of_IN CCs_NNP [_NN 3_CD 4_CD 5_CD 6_CD ]_NN ._. These_DT findings_NNS suggest_VBP the_DT presence_NN of_IN
        positively_RB regulated_VBN amplified_VBN oncogenes_NNS and_CC negatively_RB
        regulated_VBN tumor_NN suppressor_NN genes_NNS (_( TSGs_NNP )_) on_IN this_DT chromosomal_NN
        arm_NN ._. Comparative_NNP genomic_JJ hybridization_NN (_( CGH_NNP )_) ,_, a_DT molecular_JJ
        cytogenetic_JJ method_NN that_WDT identifies_VBZ chromosomal_NN gains_NNS and_CC
        losses_NNS ,_, and_CC loss_NN of_IN heterozygosity_NN (_( LOH_NNP )_) studies_NNS have_VBP also_RB
        demonstrated_VBN recurrent_JJ deletions_NNS on_IN the_DT 5_CD p_NN in_IN precancerous_JJ
        lesions_NNS [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ._. Although_IN ,_, these_DT studies_NNS have_VBP
        identified_VBN 5_CD p_NN as_IN a_DT commonly_RB affected_VBN region_NN ,_, the_DT precise_JJ
        site_NN of_IN deletion_NN that_DT harbor_NN putative_JJ TSG_NNP is_VBZ unknown_JJ
        because_IN of_IN the_DT lack_NN of_IN systematic_JJ and_CC detailed_JJ deletion_NN
        mapping_NN studies_NNS ._.
        To_TO further_VB characterize_VB the_DT 5_CD p_NN region_NN in_IN CC_NNP ,_, we_PRP
        performed_VBD a_DT high-resolution_JJ deletion_NN mapping_NN in_IN invasive_JJ
        cancer_NN and_CC found_VBD that_IN 60_CD %_NN of_IN patients_NNS exhibit_NN LOH_NNP ._. We_PRP
        identified_VBD two_CD sites_NNS of_IN minimal_JJ deletions_NNS at_IN 5_CD p_NN 15_CD ._. 3_LS and_CC
        5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS spanning_VBG 5_CD ._. 5_CD cM_NN and_CC 7_CD cM_NN genetic_JJ distance_NN ,_,
        respectively_RB ._. We_PRP have_VBP also_RB shown_VBN that_IN the_DT 5_CD p_NN 15_CD region_NN
        deletions_NNS occur_VBP in_IN 16_CD %_NN of_IN high-grade_JJ CIN_NNP lesions_NNS ._. Here_RB ,_, we_PRP
        have_VBP identified_VBN two_CD sites_NNS of_IN candidate_NN tumor_NN suppressor_NN
        genes_NNS and_CC confirmed_VBD the_DT previous_JJ reports_NNS that_IN the_DT 5_CD p_NN
        deletions_NNS occur_VBP in_IN a_DT small_JJ proportion_NN of_IN precancerous_JJ
        lesions_NNS ._.
      
      
        Results_NNS
        
          Identification_NNP of_IN two_CD regions_NNS of_IN minimal_JJ deletions_NNS
          at_IN 5_CD p_NN 15_CD ._. 2_LS -_: p_NN 15_CD ._. 3_LS
          Analysis_NNP of_IN LOH_NNP in_IN 60_CD invasive_JJ CCs_NNP using_VBG 20_CD STRP_NNP
          markers_NNS mapped_VBN to_TO 5_CD p_NN showed_VBD deletions_NNS in_IN 36_CD of_IN 60_CD (_( 60_CD %_NN )_)
          tumors_NNS in_IN at_IN least_JJS one_CD marker_NN (_( Table_NNP 1_LS )_) ._. Of_IN the_DT 36_CD tumors_NNS
          with_IN LOH_NNP ,_, 17_CD (_( 47_CD ._. 2_LS %_NN )_) had_VBD LOH_NNP at_IN all_PDT the_DT informative_JJ
          markers_NNS suggesting_VBG genetic_JJ monosomy_NN of_IN 5_CD p_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT
          patterns_NNS of_IN LOH_NNP in_IN the_DT remaining_VBG 19_CD tumors_NNS that_WDT exhibited_VBN
          regional_JJ losses_NNS on_IN 5_CD p_NN were_VBD used_VBN to_TO map_VB the_DT common_JJ deleted_VBN
          regions_NNS (_( Fig_NNP ._. 1_LS )_) ._. This_DT has_VBZ identified_VBN two_CD minimal_JJ
          deletions_NNS at_IN 5_CD p_NN 15_CD ._. 3_LS and_CC 5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS (_( Fig_NNP ._. 1_LS &_CC Fig_NNP ._. 2_LS )_) ._.
          All_DT the_DT tumors_NNS that_WDT defined_VBD the_DT minimal_JJ deletions_NNS showed_VBD
          more_JJR than_IN 60_CD %_NN reduction_NN in_IN signal_NN intensity_NN in_IN the_DT
          deleted_VBN alleles_NNS ._.
          The_DT distal_NN 5_CD p_NN 15_CD ._. 3_LS deletion_NN spans_NNS the_DT telomeric_JJ region_NN
          encompassing_VBG D_NNP 5_CD S_NNP 392_CD ,_, D_NNP 5_CD S_NNP 678_CD ,_, and_CC D_NNP 5_CD S_NNP 417_CD markers_NNS in_IN 32_CD
          tumors_NNS ._. Although_IN two_CD tumors_NNS (_( T-_NNP 13_CD and_CC T-_NNP 49_CD )_) showed_VBD
          deletions_NNS of_IN terminal_NN marker_NN D_NNP 5_CD S_NNP 392_CD alone_RB at_IN 0_CD cM_NN genetic_JJ
          distance_NN ,_, which_WDT is_VBZ the_DT distal_NN most_JJS marker_NN on_IN 5_CD p_NN ,_, we_PRP
          considered_VBD the_DT deletion_NN boundaries_NNS defined_VBN by_IN the_DT
          proximal_NN marker_NN D_NNP 5_CD S_NNP 417_CD in_IN tumors_NNS T-_NNP 6_CD and_CC T-_NNP 105_CD (_( Fig_NNP ._.
          1_LS &_CC Fig_NNP ._. 2_LS )_) ._. The_DT second_NN and_CC proximal_NN region_NN of_IN
          deletion_NN spans_NNS 6_CD markers_NNS (_( D_NNP 5_CD S_NNP 406_CD ,_, GATA_NNP 82_CD H_NNP 02_CD ,_, D_NNP 5_CD S_NNP 1455_CD ,_,
          D_NNP 5_CD S_NNP 2054_CD ,_, D_NNP 5_CD S_NNP 635_CD and_CC D_NNP 5_CD S_NNP 676_CD )_) ,_, and_CC was_VBD deleted_VBN in_IN 28_CD
          tumors_NNS ._. The_DT deletion_NN boundaries_NNS were_VBD defined_VBN proximally_RB
          by_IN the_DT tumors_NNS T-_NNP 59_CD and_CC T-_NNP 66_CD ,_, while_IN the_DT distal_NN boundary_NN
          was_VBD identified_VBN by_IN the_DT tumors_NNS T-_NNP 59_CD and_CC T-_NNP 114_CD (_( Fig_NNP ._. 1_LS &_CC
          Fig_NNP ._. 2_LS )_) ._. All_DT tumors_NNS that_WDT showed_VBD 5_CD p_NN deletions_NNS fell_VBD within_IN
          the_DT two_CD defined_VBN regions_NNS of_IN deletions_NNS ,_, while_IN 25_CD tumors_NNS
          exhibited_VBN deletions_NNS at_IN both_DT regions_NNS ._. Thus_RB ,_, this_DT analysis_NN
          identified_VBD two_CD discrete_JJ and_CC closely_RB mapped_VBN sites_NNS of_IN
          minimal_JJ deletions_NNS at_IN 5_CD p_NN 15_CD ._. 3_LS and_CC 5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS ,_, which_WDT were_VBD
          restricted_VBN to_TO 5_CD ._. 5_CD cM_NN and_CC 7_CD cM_NN genetic_JJ distance_NN ,_,
          respectively_RB ._.
        
        
          Gene_NNP expression_NN analysis_NN of_IN candidate_NN tumor_NN
          suppressor_NN genes_NNS in_IN CC_NNP cell_NN lines_NNS
          In_IN an_DT effort_NN to_TO identify_VB the_DT genes_NNS inactivated_JJ in_IN the_DT
          recurrent_JJ 5_CD p_NN deletions_NNS in_IN CC_NNP ,_, we_PRP identified_VBD candidate_NN
          genes_NNS with_IN tumor_NN suppressor_NN function_NN ._. Three_CD genes_NNS were_VBD
          identified_VBN at_IN the_DT terminal_NN 5_CD p_NN 15_CD ._. 3_LS deletion_NN ._. These_DT
          include_VBP ,_, 
          PDCD_NNP 6_CD ,_, a_DT protein_NN that_WDT plays_VBZ a_DT role_NN
          in_IN T_NN cell_NN receptor-_NN ,_, FAS-_NNP ,_, and_CC glucocorticoid-induced_JJ
          cell_NN death_NN [_NN 11_CD ]_NN ;_: 
          TERT_NNP ,_, a_DT gene_NN that_IN encodes_NNS a_DT
          reverse_JJ transcriptase_NN component_NN of_IN telomerase_NN ,_,
          dysfunction_NN of_IN which_WDT promotes_VBZ chromosomal_NN instability_NN [_NN
          12_CD ]_NN ;_: and_CC 
          TRIP_NNP 13_CD ,_, a_DT thyroid_NN hormone_NN receptor_NN
          interacting_VBG protein_NN that_IN binds_NNS with_IN the_DT human_JJ
          papillomavirus_JJ type_NN 16_CD (_( HPV_NNP 16_CD )_) E_NNP 1_CD protein_NN [_NN 13_CD ]_NN ._. We_PRP
          have_VBP identified_VBN 
          POLS_NNP gene_NN that_IN encodes_NNS a_DT DNA_NNP
          polymerase_NN sigma_NN ,_, and_CC plays_VBZ a_DT role_NN in_IN DNA_NNP replication_NN and_CC
          sister_NN chromatid_NN cohesion_NN at_IN the_DT proximal_NN minimal_JJ deleted_VBN
          region_NN [_NN 14_CD ]_NN ._. We_PRP performed_VBD a_DT semi-quantitative_JJ RT-PCR_NNP
          analysis_NN of_IN all_DT four_CD genes_NNS (_( 
          PDCD_NNP 6_CD ,_, 
          TERT_NNP ,_, 
          TRIP_NNP 13_CD ,_, and_CC 
          POLS_NNP )_) in_IN eight_CD CC_NNP cell_NN lines_NNS and_CC
          did_VBD not_RB find_VB evidence_NN for_IN lack_NN of_IN or_CC down_RB regulated_VBN
          expression_NN compared_VBN to_TO normal_JJ cervix_NN (_( Fig_NNP ._. 3_LS )_) ._.
        
        
          5_LS p_NN deletions_NNS in_IN relation_NN to_TO HPV_NNP
          5_LS p_NN deletions_NNS did_VBD not_RB show_VB any_DT significant_JJ differences_NNS
          with_IN age_NN at_IN diagnosis_NN and_CC stage_NN of_IN the_DT tumor_NN (_( data_NNS not_RB
          shown_VBN )_) ._. Fifty-eight_NNP (_( 96_CD ._. 7_CD %_NN )_) of_IN the_DT 60_CD tumors_NNS studied_VBN were_VBD
          positive_JJ for_IN HPV_NNP DNA_NNP ._. The_DT remaining_VBG two_CD tumors_NNS were_VBD
          HPV-negative_NNP ._. HPV_NNP 16_CD alone_RB or_CC in_IN combination_NN with_IN other_JJ
          HPV_NNP types_NNS was_VBD found_VBN in_IN 46_CD tumors_NNS ,_, while_IN 12_CD tumors_NNS had_VBD
          other_JJ HPV_NNP types_NNS including_VBG HPV_NNP 18_CD ._. 5_LS p_NN LOH_NNP was_VBD found_VBN in_IN 29_CD
          of_IN 46_CD (_( 63_CD %_NN )_) HPV_NNP 16_CD positive_JJ tumors_NNS ,_, while_IN only_RB 4_CD of_IN 12_CD
          (_( 33_CD %_NN )_) tumors_NNS with_IN other_JJ HPV-types_NNP had_VBD 5_CD p_NN LOH_NNP ._. The_DT two_CD
          tumors_NNS that_WDT did_VBD not_RB harbor_NN HPV_NNP infection_NN also_RB had_VBD LOH_NNP at_IN
          5_CD p_NN ._. These_DT differences_NNS were_VBD found_VBN to_TO be_VB statistically_RB not_RB
          significant_JJ (_( Chi_NNP square_JJ 4_CD ._. 93_CD ;_: p_NN =_SYM 0_CD ._. 10_CD )_) ._. However_RB ,_, when_WRB
          the_DT analysis_NN was_VBD restricted_VBN to_TO HPV_NNP 16_CD harboring_VBG tumors_NNS ,_, it_PRP
          was_VBD found_VBN that_IN the_DT patients_NNS harboring_VBG HPV_NNP 16_CD DNA_NNP alone_RB had_VBD
          5_CD p_NN LOH_NNP in_IN 20_CD of_IN 36_CD (_( 55_CD ._. 6_CD %_NN )_) tumors_NNS ,_, while_IN the_DT patients_NNS
          infected_VBN with_IN HPV_NNP 16_CD in_IN combination_NN with_IN other_JJ HPV_NNP types_NNS
          exhibited_VBN 9_CD of_IN 10_CD (_( 90_CD %_NN )_) LOH_NNP ._. This_DT difference_NN was_VBD found_VBN to_TO
          be_VB statistically_RB significant_JJ (_( Chi_NNP square_NN ,_, 8_CD ._. 75_CD ;_: p_NN =_SYM
          0_CD ._. 05_CD )_) ._.
        
        
          5_LS p_NN deletions_NNS occur_VBP at_IN low_JJ frequency_NN in_IN precancerous_JJ
          lesions_NNS
          To_TO understand_VB the_DT role_NN of_IN 5_CD p_NN deletions_NNS in_IN cervical_JJ
          cancer_NN progression_NN ,_, we_PRP evaluated_VBD LOH_NNP in_IN 26_CD microdissected_JJ
          CIN_NNP specimens_NNS (_( 25_CD high-grade_JJ CINs_NNP and_CC one_CD low-grade_JJ CIN_NNP )_)
          using_VBG four_CD STRP_NNP markers_NNS (_( Table_NNP 2_LS )_) ._. Four_CD of_IN the_DT 25_CD
          informative_JJ tumors_NNS had_VBD LOH_NNP at_IN one_CD or_CC more_JJR markers_NNS ._. One_CD
          low-grade_JJ CIN_NNP did_VBD not_RB show_VB LOH_NNP ._. Thus_RB ,_, deletions_NNS at_IN 5_CD p_NN
          identified_VBN in_IN high-grade_JJ CINs_NNP suggest_VBP that_IN these_DT genetic_JJ
          alterations_NNS occur_VBP prior_RB to_TO development_NN of_IN invasive_JJ
          carcinoma_NN ._.
        
      
      
        Discussion_NNP
        Extensive_NNP genetic_JJ studies_NNS have_VBP documented_VBN frequent_JJ
        alterations_NNS affecting_VBG various_JJ chromosomal_NN regions_NNS in_IN CC_NNP ._.
        LOH_NNP and_CC CGH_NNP analyses_NNS have_VBP consistently_RB shown_VBN frequent_JJ loss_NN
        of_IN genomic_JJ material_NN in_IN a_DT number_NN of_IN chromosomal_NN regions_NNS
        suggesting_VBG the_DT presence_NN of_IN potential_JJ tumor_NN suppressor_NN genes_NNS
        at_IN these_DT sites_NNS [_NN 4_CD 6_CD 15_CD 16_CD ]_NN ._. Of_IN these_DT ,_, chromosome_NN 5_CD p_NN
        deletions_NNS have_VBP been_VBN noted_VBN to_TO be_VB very_RB frequent_JJ in_IN invasive_JJ
        CC_NNP [_NN 5_CD 6_CD 7_CD ]_NN ._. However_RB ,_, the_DT locations_NNS of_IN exact_JJ regions_NNS of_IN
        LOH_NNP are_VBP not_RB known_VBN because_IN of_IN a_DT lack_NN of_IN systematic_JJ and_CC
        high-resolution_JJ deletion_NN mapping_NN of_IN the_DT 5_CD p_NN region_NN in_IN CC_NNP ._. We_PRP
        have_VBP previously_RB identified_VBN that_IN markers_NNS mapped_VBN to_TO 5_CD p_NN 15_CD
        regions_NNS are_VBP more_RBR frequently_RB deleted_VBN [_NN 4_CD 7_CD ]_NN ._. To_TO further_VB
        characterize_VB the_DT 5_CD p_NN deletions_NNS in_IN CC_NNP ,_, we_PRP performed_VBD a_DT
        high-density_JJ LOH_NNP mapping_NN in_IN the_DT present_JJ study_NN ._. We_PRP found_VBD
        high_JJ frequency_NN of_IN LOH_NNP and_CC identified_VBN two_CD minimal_JJ regions_NNS of_IN
        deletions_NNS at_IN 5_CD p_NN 15_CD ._. 3_LS and_CC 5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS ._.
        The_DT 5_CD p_NN 15_CD ._. 3_LS minimal_JJ deletion_NN spans_NNS between_IN 0_CD -_: 5_CD ._. 5_LS cM_NN
        genetic_JJ distance_NN ._. Consistent_NNP with_IN this_DT pattern_NN ,_, the_DT markers_NNS
        D_NNP 5_CD S_NNP 392_CD and_CC D_NNP 5_CD S_NNP 417_CD exhibited_VBN the_DT highest_JJS frequency_NN (_( 53_CD ._. 8_CD %_NN
        and_CC 53_CD ._. 6_CD %_NN ,_, respectively_RB )_) of_IN LOH_NNP among_IN all_PDT the_DT tested_VBN loci_NN ._.
        The_DT genomic_JJ size_NN of_IN the_DT 5_CD p_NN 15_CD ._. 3_LS deletion_NN interval_NN is_VBZ
        approximately_RB 3_CD ._. 2_CD Mb_NNP ._. A_DT database_NN search_NN has_VBZ identified_VBN
        three_CD candidate_NN genes_NNS ,_, 
        PDCD_NNP 6_CD ,_, 
        TERT_NNP ,_, and_CC 
        TRIP_NNP 13_CD ,_, with_IN suggestive_JJ tumor_NN
        suppressor_NN gene_NN function_NN ._. The_DT programmed_VBN cell_NN death_NN gene_NN ,_, 
        PDCD_NNP 6_CD ,_, is_VBZ a_DT member_NN of_IN the_DT family_NN of_IN
        intracellular_NN Ca_MD 2_CD +_NN -_: binding_JJ proteins_NNS and_CC a_DT part_NN of_IN the_DT
        apoptotic_JJ machinery_NN controlled_VBN by_IN T-_NNP cell_NN receptor_NN (_( TCR_NNP )_) ,_,
        Fas_NNP ,_, and_CC glucocorticoid_NN signals_NNS [_NN 11_CD 17_CD ]_NN ._. 
        TERT_NNP encodes_NNS a_DT reverse_JJ transcriptase_NN
        required_VBN for_IN the_DT replication_NN of_IN chromosome_NN termini_NN and_CC
        plays_VBZ a_DT role_NN in_IN telomere_NN elongation_NN ._. Although_IN telomerase_NN
        expression_NN is_VBZ a_DT hallmark_NN of_IN cancer_NN ,_, the_DT mice_NNS lacking_VBG the_DT
        RNA_NNP component_NN of_IN telomerase_NN (_( mTERC_NN )_) exhibit_NN progressive_JJ
        telomere_NN shortening_NN and_CC chromosomal_NN instability_NN associated_VBN
        with_IN epithelial_NN tumors_NNS [_NN 12_CD ]_NN ._. Consistent_NNP with_IN the_DT
        established_VBN role_NN of_IN this_DT enzyme_NN in_IN cell_NN immortalization_NN and_CC
        cancer_NN pathogenesis_NNS [_NN 18_CD ]_NN ,_, we_PRP did_VBD not_RB find_VB expression_NN in_IN
        normal_JJ cervix_NN while_IN it_PRP was_VBD abundantly_RB present_JJ in_IN all_DT eight_CD
        cell_NN lines_NNS studied_VBN (_( Fig_NNP ._. 3_LS )_) ._. Recently_RB ,_, it_PRP has_VBZ been_VBN shown_VBN
        that_IN the_DT hTERT_NN amplification_NN and_CC over_IN expression_NN is_VBZ common_JJ
        in_IN CC_NNP [_NN 19_CD ]_NN ._. 
        TRIP_NNP 13_CD ,_, thyroid_NN receptor_NN interacting_VBG
        protein_NN 13_CD ,_, is_VBZ a_DT transcription_NN factor_NN that_WDT regulates_VBZ
        expression_NN of_IN a_DT variety_NN of_IN specific_JJ target_NN genes_NNS including_VBG
        the_DT human_JJ papillomavirus_JJ type_NN 16_CD (_( HPV_NNP 16_CD )_) E_NNP 1_CD protein_NN [_NN 13_CD ]_NN
        ._. Similar_JJ to_TO 
        TERT_NNP ,_, the_DT 
        TRIP_NNP 13_CD also_RB showed_VBD very_RB low_JJ
        expression_NN in_IN normal_JJ cervix_NN and_CC highly_RB elevated_VBD levels_NNS of_IN
        expression_NN in_IN CC_NNP cell_NN lines_NNS (_( Fig_NNP ._. 3_LS )_) ._. Presence_NNP of_IN these_DT
        genes_NNS at_IN the_DT 5_CD p_NN 15_CD ._. 3_LS interval_NN suggests_VBZ that_IN they_PRP may_MD be_VB
        target_NN TSGs_NNP of_IN these_DT deletions_NNS in_IN CC_NNP ._. However_RB ,_, expression_NN
        analysis_NN of_IN these_DT genes_NNS did_VBD not_RB provide_VB evidence_NN of_IN
        down-regulation_JJ in_IN CC_NNP cell_NN lines_NNS ._.
        The_DT second_JJ site_NN of_IN minimal_JJ deletion_NN at_IN 5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS
        between_IN 10_CD ._. 7_CD and_CC 17_CD ._. 7_CD cM_NN genetic_JJ distance_NN spans_NNS
        approximately_RB 2_CD ._. 5_CD Mb_NNP genomic_JJ region_NN ._. A_DT database_NN search_NN has_VBZ
        identified_VBN 
        POLS_NNP ,_, a_DT topoisomerase-related_JJ
        function_NN protein-_NN 4_CD -_: 1_CD ,_, gene_NN that_IN encodes_NNS polymerase_NN (_( DNA_NNP
        directed_VBD )_) sigma_NN within_IN the_DT deleted_VBN region_NN ._. The_DT yeast_NN
        homolog_NN TRF_NNP 4_CD plays_VBZ a_DT critical_JJ role_NN in_IN chromosome_NN
        segregation_NN by_IN coordinating_VBG between_IN DNA_NNP replication_NN and_CC
        sister_NN chromatid_NN cohesion_NN [_NN 14_CD ]_NN ._. Analysis_NNP of_IN expression_NN
        of_IN this_DT gene_NN in_IN CC_NNP cell_NN lines_NNS did_VBD not_RB show_VB evidence_NN of_IN down_RB
        regulation_NN ._. Although_IN the_DT genes_NNS tested_VBN so_RB far_RB showed_VBD no_DT
        deregulated_VBN expression_NN ,_, it_PRP remains_VBZ to_TO be_VB seen_VBN whether_IN any_DT
        of_IN these_DT genes_NNS or_CC the_DT others_NNS mapped_VBN to_TO the_DT minimal_JJ deleted_VBN
        regions_NNS are_VBP targets_NNS of_IN mutations_NNS in_IN CC_NNP ._. However_RB ,_, the_DT
        present_JJ study_NN identified_VBD two_CD discrete_JJ sites_NNS of_IN deletions_NNS at_IN
        5_CD p_NN 15_CD ._. 3_LS and_CC 5_CD p_NN 15_CD ._. 2_LS -_: 15_CD ._. 3_LS that_DT harbor_NN putative_JJ TSGs_NNP important_JJ
        in_IN CC_NNP development_NN providing_VBG a_DT basis_NN for_IN their_PRP$
        identification_NN ._.
        5_LS p_NN deletions_NNS also_RB have_VBP been_VBN reported_VBN in_IN precursor_NN CIN_NNP
        lesions_NNS with_IN the_DT frequencies_NNS between_IN 14_CD ._. 7_CD and_CC 42_CD %_NN [_NN 7_CD 8_CD 9_CD
        10_CD ]_NN ._. We_PRP have_VBP previously_RB shown_VBN ,_, in_IN a_DT different_JJ
        geographical_JJ population_NN ,_, that_IN 21_CD %_NN of_IN CINs_NNP had_VBD 5_CD p_NN deletions_NNS ._.
        Based_VBN on_IN the_DT follow-up_JJ studies_NNS ,_, we_PRP suggested_VBD that_IN 5_CD p_NN
        genetic_JJ deletions_NNS might_MD identify_VB high-risk_JJ lesions_NNS for_IN
        progression_NN to_TO invasive_JJ cancer_NN [_NN 7_CD ]_NN ._. In_IN a_DT more_RBR recent_JJ
        study_NN it_PRP was_VBD also_RB shown_VBN that_IN the_DT 5_CD p_NN deletions_NNS were_VBD
        significantly_RB more_RBR frequent_JJ in_IN dysplasias_NNS that_WDT were_VBD
        recurrent_JJ compared_VBN to_TO non-recurrent_JJ dysplasias_NNS [_NN 9_CD ]_NN ._.
        These_DT data_NNS therefore_RB suggest_VBP that_IN 5_CD p_NN genetic_JJ alterations_NNS
        occur_VBP early_RB in_IN cervical_JJ carcinogenesis_NNS and_CC they_PRP may_MD be_VB
        critical_JJ to_TO the_DT development_NN of_IN invasive_JJ cancer_NN ._. Supporting_VBG
        previous_JJ reports_NNS ,_, in_IN the_DT present_JJ study_NN ,_, we_PRP detected_VBD LOH_NNP at_IN
        5_CD p_NN 15_CD in_IN 16_CD %_NN of_IN the_DT high-grade_JJ CINs_NNP (_( Table_NNP 2_LS )_) ._.
        The_DT role_NN and_CC mechanisms_NNS involved_VBN in_IN high-risk_JJ HPV_NNP
        induced_VBD genomic_JJ instability_NN has_VBZ been_VBN of_IN a_DT considerable_JJ
        speculation_NN [_NN reviewed_VBN in_IN ref_NN ._. [_NN 20_CD ]_NN ]_NN ._. High-risk_NNP HPV_NNP E_NNP 6_CD
        and_CC E_NNP 7_CD gene_NN expression_NN can_MD independently_RB immortalize_NN
        various_JJ human_JJ cell_NN types_NNS 
        in_IN vitro_NN ._. The_DT E_NNP 6_CD gene_NN interacts_NNS with_IN
        p_NN 53_CD and_CC an_DT apoptotic_JJ protein_NN 
        BAK_NNP ,_, followed_VBN by_IN its_PRP$ degradation_NN ,_,
        which_WDT results_VBZ in_IN chromosomal_NN instability_NN and_CC resistance_NN to_TO
        apoptosis_NNS [_NN 21_CD 22_CD ]_NN ._. The_DT E_NNP 7_CD protein_NN interacts_NNS with_IN pRB_NN
        followed_VBN by_IN its_PRP$ degradation_NN [_NN 23_CD ]_NN ._. The_DT p_NN 53_CD and_CC pRB_NN
        proteins_NNS have_VBP been_VBN shown_VBN to_TO play_VB multiple_JJ roles_NNS in_IN cell_NN
        growth_NN and_CC in_IN genomic_JJ integrity_NN ._. There_EX have_VBP been_VBN
        contradictory_JJ reports_NNS on_IN targeted_VBN 5_CD p_NN deletions_NNS in_IN relation_NN
        to_TO HPV_NNP infection_NN [_NN 5_CD 24_CD ]_NN ._. Ku_NNP and_CC co-workers_NNS have_VBP shown_VBN
        that_IN 5_CD p_NN deletions_NNS occur_VBP in_IN significantly_RB high_JJ proportion_NN of_IN
        CC_NNP infected_VBN with_IN HPV_NNP 16_CD compared_VBN to_TO low-risk_JJ HPVtypes_NNP [_NN 5_CD ]_NN
        ._. Contradictory_NNP to_TO this_DT ,_, another_DT study_NN has_VBZ shown_VBN that_IN 5_CD p_NN
        deletions_NNS are_VBP independent_JJ of_IN HPV_NNP 16_CD and_CC HPV_NNP 18_CD infection_NN [_NN 24_CD
        ]_NN ._. In_IN the_DT present_JJ study_NN ,_, we_PRP did_VBD not_RB find_VB any_DT significant_JJ
        differences_NNS in_IN 5_CD p_NN LOH_NNP between_IN patients_NNS harboring_VBG HPV_NNP 16_CD and_CC
        other_JJ HPV_NNP types_NNS ._. However_RB ,_, we_PRP found_VBD that_IN patients_NNS harboring_VBG
        HPV_NNP 16_CD in_IN combination_NN with_IN other_JJ HPV_NNP types_NNS showed_VBD
        significant_JJ increase_NN in_IN 5_CD p_NN loss_NN compared_VBN to_TO patients_NNS
        harboring_VBG HPV_NNP 16_CD alone_RB ._. These_DT data_NNS ,_, therefore_RB ,_, suggest_VBP that_IN
        multiple_JJ high-risk_JJ HPV_NNP infections_NNS may_MD have_VB synergistic_JJ
        effect_NN in_IN causing_VBG genomic_JJ instability_NN ._. Thus_RB ,_, currently_RB it_PRP
        is_VBZ unclear_JJ the_DT role_NN of_IN high-risk_JJ HPV_NNP types_NNS in_IN causing_VBG 5_CD p_NN
        genomic_JJ instability_NN ._. Further_RB studies_VBZ are_VBP needed_VBN to_TO address_VB
        this_DT question_NN ._.
      
      
        Conclusions_NNP
        In_IN summary_NN ,_, the_DT present_JJ study_NN confirms_VBZ our_PRP$ previous_JJ
        observations_NNS that_IN genetic_JJ loss_NN of_IN 5_CD p_NN is_VBZ a_DT common_JJ feature_NN of_IN
        invasive_JJ CC_NNP ._. Here_RB we_PRP identified_VBD two_CD common_JJ sites_NNS of_IN
        deletions_NNS that_WDT harbor_NN candidate_NN tumor_NN suppressor_NN genes_NNS on_IN
        this_DT chromosomal_NN arm_NN and_CC showed_VBD that_IN multiple_JJ infection_NN of_IN
        high-risk_JJ HPV_NNP types_NNS may_MD cause_VB targeted_VBN genomic_JJ instability_NN
        at_IN 5_CD p_NN ._. In_IN addition_NN ,_, we_PRP have_VBP shown_VBN that_IN the_DT genetic_JJ
        deletions_NNS on_IN 5_CD p_NN occur_VB early_RB during_IN the_DT development_NN of_IN CC_NNP in_IN
        high-grade_JJ CIN_NNP lesions_NNS ._. Our_PRP$ identification_NN of_IN minimal_JJ
        deletions_NNS on_IN 5_CD p_NN and_CC LOH_NNP in_IN CINs_NNP has_VBZ several_JJ potential_JJ
        implications_NNS ._. First_LS ,_, it_PRP should_MD facilitate_VB the_DT
        identification_NN of_IN the_DT target_NN genes_NNS of_IN importance_NN in_IN
        cervical_JJ tumorigenesis_NNS ._. Second_JJ ,_, it_PRP may_MD provide_VB critical_JJ
        genetic_JJ markers_NNS for_IN identifying_VBG cervical_JJ intraepithelial_NN
        neoplasias_NNS at_IN high-risk_JJ to_TO progression_NN ._.
      
      
        Methods_NNP
        
          Tumor_NNP and_CC normal_JJ tissues_NNS
          We_PRP analyzed_VBD 60_CD tumor_NN biopsies_NNS consisting_VBG of_IN previously_RB
          untreated_JJ primary_JJ invasive_JJ CCs_NNP with_IN the_DT corresponding_JJ
          peripheral_JJ blood_NN samples_NNS ,_, and_CC 26_CD formalin-fixed_JJ and_CC
          paraffin-embedded_JJ CIN_NNP specimens_NNS ._. The_DT tissues_NNS were_VBD
          obtained_VBN from_IN patients_NNS treated_VBN at_IN the_DT Instituto_NNP Nacional_NNP
          de_IN Cancerologia_NNP ,_, Colombia_NNP after_IN appropriate_JJ informed_VBN
          consent_NN and_CC approval_NN of_IN the_DT protocols_NNS by_IN the_DT
          institutional_JJ review_NN board_NN ._. The_DT invasive_JJ tumors_NNS were_VBD
          clinically_RB classified_VBN as_IN FIGO_NNP stage_NN IB_NNP (_( 5_CD tumors_NNS )_) ,_, IIB_NNP
          (_( 14_CD tumors_NNS )_) ,_, IIIB_NNP (_( 37_CD tumors_NNS )_) ,_, and_CC IV_NNP (_( 4_CD tumors_NNS )_) ._.
          Histologically_NNP ,_, 57_CD tumors_NNS were_VBD classified_VBN as_IN squamous_JJ
          cell_NN carcinomas_NNS and_CC 3_CD as_IN adenocarcinomas_NNS ._. Twenty-five_CD CIN_NNP
          specimens_NNS were_VBD classified_VBN as_IN high-grade_JJ and_CC one_CD as_IN
          low-grade_JJ lesions_NNS ._. Eight_CD CC_NNP cell_NN lines_NNS SiHa_NNP ,_, SW_NNP 756_CD ,_, C-_NNP 4_CD I_PRP ,_,
          Ca_NNP Ski_NN ,_, C-_NNP 33_CD A_DT ,_, HT-_NNP 3_CD ,_, MS_NNP 751_CD and_CC ME-_NNP 180_CD were_VBD obtained_VBN from_IN
          the_DT American_NNP Type_NNP Culture_NNP Collection_NNP (_( ATCC_NNP ,_, Manassas_NNP ,_,
          VA_NNP )_) ,_, and_CC were_VBD grown_VBN in_IN culture_NN according_VBG to_TO the_DT
          supplier_NN 's_POS recommendations_NNS ._.
        
        
          Microdissection_NNP ,_, DNA_NNP and_CC RNA_NNP isolation_NN and_CC LOH_NNP
          analysis_NN
          High-molecular_NNP weight_NN DNA_NNP from_IN frozen_VBN tumor_NN and_CC the_DT
          corresponding_JJ peripheral_JJ blood_NN specimens_NNS ,_, and_CC frozen_VBN
          cells_NNS from_IN cell_NN lines_NNS was_VBD isolated_VBN as_RB previously_RB
          described_VBD [_NN 25_CD ]_NN ._. Tumor_NNP cells_NNS from_IN paraffin-embedded_JJ CIN_NNP
          tissue_NN specimens_NNS were_VBD isolated_VBN by_IN laser_NN capture_NN
          microdissection_NN (_( Arcturus_NNP ,_, Mountain_NNP View_NNP ,_, CA_NNP )_) after_IN
          methyl_NN green-staining_JJ and_CC the_DT extraction_NN of_IN DNA_NNP as_IN
          described_VBN earlier_JJR [_NN 26_CD ]_NN ._. Total_NNP RNA_NNP was_VBD isolated_VBN from_IN
          semi-confluent_JJ cell_NN cultures_NNS using_VBG the_DT TRIzol_NNP reagent_NN
          (_( Life_NNP Technologies_NNPS ,_, Gaithersburg_NNP ,_, MD_NNP )_) according_VBG to_TO the_DT
          manufacturer_NN 's_POS protocol_NN ._. A_DT panel_NN of_IN 20_CD sequence_NN tagged_VBN
          repeat_NN polymorphic_JJ (_( STRP_NNP )_) (_( 18_CD di-_NN and_CC two_CD
          tetra-nucleotide_JJ )_) markers_NNS was_VBD chosen_VBN on_IN the_DT basis_NN of_IN
          their_PRP$ map_NN position_NN and_CC heterozygosity_NN (_( Fig_NNP ._. 1_LS )_) (_( Gene_NNP Map_NNP
          99_CD -_: http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN genemap_NN )_) ._. A_DT standard_JJ
          polymerase_NN chain_NN reaction_NN (_( PCR_NNP )_) containing_VBG gamma_NN [_NN 32_CD P_NN ]_NN
          ATP_NNP end-labeled_JJ forward_RB primer_NN ,_, analysis_NN of_IN PCR_NNP products_NNS
          on_IN denaturing_VBG polyacrylamide_NN sequencing_VBG gels_NNS ,_, and_CC scoring_VBG
          of_IN LOH_NNP on_IN autoradiograms_NNS was_VBD performed_VBN as_RB previously_RB
          described_VBD [_NN 25_CD 26_CD ]_NN ._. All_DT autoradiograms_NNS were_VBD visually_RB
          analyzed_VBN ._. Reduction_NNP of_IN signal_NN intensity_NN by_IN 50_CD %_NN or_CC more_JJR of_IN
          one_CD allele_NN over_IN the_DT other_JJ allele_NN in_IN tumor_NN DNA_NNP compared_VBD
          with_IN the_DT intensity_NN of_IN constitutional_JJ alleles_NNS was_VBD
          considered_VBN LOH_NNP ._. The_DT definition_NN of_IN minimal_JJ region_NN of_IN
          deletion_NN was_VBD defined_VBN earlier_JJR [_NN 25_CD ]_NN ._. The_DT LOH_NNP analysis_NN
          was_VBD performed_VBN at_IN least_JJS twice_RB on_IN all_DT tumors_NNS with_IN the_DT
          corresponding_JJ markers_NNS that_WDT define_VB the_DT minimal_JJ
          deletions_NNS ._.
        
        
          Detection_NNP of_IN HPV_NNP types_NNS
          The_DT PGMY_NNP 09_CD /_NN 11_CD L_NNP 1_CD consensus_NN HPV_NNP L_NNP 1_CD primers_NNS and_CC reverse_VB
          line_NN blot_NN hybridization_NN system_NN was_VBD used_VBN to_TO detect_VB 38_CD
          genital_JJ HPV_NNP types_NNS as_IN described_VBN earlier_JJR [_NN 27_CD 28_CD ]_NN ._.
          Appropriate_NNP control_NN experiments_NNS were_VBD set_VBN up_RP using_VBG bulk_NN
          master_NN mix_NN components_NNS to_TO eliminate_VB potential_JJ
          contamination_NN ._. Individual_JJ assay_NN sensitivity_NN was_VBD analyzed_VBN
          by_IN the_DT use_NN of_IN serial_NN dilutions_NNS of_IN SiHa_NNP cell_NN line_NN crude_NN
          cell_NN digest_VB ,_, targeting_VBG 10_CD 4_CD ,_, 10_CD 3_CD ,_, 10_CD 2_CD ,_, 10_CD 1_CD ,_, and_CC 10_CD
          0_CD input_NN copies_NNS of_IN HPV-_NNP 16_CD ._. A_DT no_DT template_NN negative_JJ control_NN
          was_VBD set_VBN up_RP in_IN all_DT experiments_NNS ._.
        
        
          Analysis_NNP of_IN gene_NN expression_NN
          Total_NNP RNA_NNP isolated_VBD from_IN the_DT cell_NN lines_NNS was_VBD reverse_VB
          transcribed_JJ using_VBG random_JJ primers_NNS and_CC the_DT Pro-_NNP STAR_NNP first_JJ
          strand_NN RT-PCR_NNP kit_NN (_( Stratagene_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) ._.
          Semi-quantitative_NNP analysis_NN of_IN gene_NN expression_NN was_VBD
          performed_VBN by_IN 26_CD to_TO 28_CD cycles_NNS of_IN multiplex_NN RT-PCR_NNP with_IN
          β-actin_JJ as_IN control_NN and_CC gene_NN specific_JJ primers_NNS spanning_VBG at_IN
          least_JJS 2_CD exons_NNS ._. The_DT gene_NN primers_NNS used_VBN and_CC their_PRP$ positions_NNS
          in_IN cDNA_NN were_VBD :_:
          
          PDCD_NNP 6_CD -_: F_NN 5_CD '_POS -_: GCTTCCTGTGGAACGTTTTC-_NNP 3_CD '_POS
          (_( 108_CD -_: 127_CD bp_NN )_)
          
          PDCD_NNP 6_CD -_: R_NN 5_CD '_POS -_: TCTTATCGATCATCCCGGAG-_NNP 3_CD '_POS
          (_( 349_CD -_: 368_CD bp_NN )_)
          
          TERT_NNP -_: F_NN 5_CD '_POS -_: GCGTTTGGTGGATGATTTCT-_NNP 3_CD '_POS
          (_( 2647_CD -_: 2666_CD bp_NN )_)
          
          TERT_NNP -_: R_NN 5_CD '_POS -_: CAGGGCCTCGTCTTCTACAG-_NNP 3_CD '_POS
          (_( 2778_CD -_: 2797_CD bp_NN )_)
          
          TRIP_NNP 13_CD -_: F_NN
          5_CD '_POS -_: CAGCAGCACTGCAAAGAAAG-_NNP 3_CD '_POS (_( 132_CD -_: 151_CD bp_NN )_)
          
          TRIP_NNP 13_CD -_: R_NN
          5_CD '_POS -_: TGTGAAGTGCAACAGTGCAT-_NNP 3_CD '_POS (_( 321_CD -_: 340_CD bp_NN )_)
          
          POLS_NNP -_: F_NN 5_CD '_POS -_: CCCTTGTCCTGAAGAAGCAG-_NNP 3_CD '_POS
          (_( 43_CD -_: 62_CD bp_NN )_)
          
          POLS_NNP -_: R_NN 5_CD '_POS -_: AGGACTTTGATGGAACACGG-_NNP 3_CD '_POS
          (_( 263_CD -_: 282_CD bp_NN )_)
          The_DT PCR_NNP products_NNS were_VBD run_VBN on_IN 1_CD ._. 5_CD -_: %_NN agarose_NN gels_NNS ,_,
          visualized_JJ by_IN ethidium_NN bromide_NN staining_VBG and_CC quantitated_JJ
          using_VBG the_DT Kodak_NNP Digital_NNP Image_NN Analysis_NNP System_NNP (_( Kodak_NNP ,_, New_NNP
          Haven_NNP ,_, CT_NNP )_) ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        Author_NN 1_CD (_( HAP_NNP )_) carried_VBD out_RP the_DT molecular_JJ genetic_JJ
        analysis_NN of_IN LOH_NNP on_IN invasive_JJ cancer_NN and_CC performed_VBN HPV_NNP
        typing_VBG ._. Author_NN 2_CD (_( GN_NNP )_) performed_VBN LOH_NNP analysis_NN on_IN CIN_NNP lesions_NNS
        and_CC gene_NN expression_NN analysis_NN ._. Author_NN 3_CD (_( HV_NNP )_) participated_VBD in_IN
        the_DT collection_NN of_IN tumor_NN material_NN and_CC clinical_JJ information_NN ._.
        Author_NN 4_CD (_( MM_NNP )_) participated_VBD in_IN microdissection_NN of_IN CIN_NNP
        lesions_NNS ._. Author_NN 5_CD (_( VVVSM_NNP )_) has_VBZ conceived_VBN and_CC coordinated_VBN the_DT
        study_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
